HC Wainwright Reaffirms Buy Rating for Kura Oncology (NASDAQ:KURA)

Kura Oncology (NASDAQ:KURA)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $32.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 72.32% from the stock’s previous close.

KURA has been the topic of a number of other research reports. Wedbush reiterated an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a report on Monday, November 4th. JMP Securities restated a “market outperform” rating and set a $32.00 price target on shares of Kura Oncology in a research note on Monday, August 12th. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research note on Wednesday, November 6th. Finally, Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and dropped their price target for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $28.83.

Kura Oncology Trading Up 5.8 %

KURA opened at $18.57 on Wednesday. Kura Oncology has a one year low of $8.17 and a one year high of $24.17. The company has a market cap of $1.44 billion, a P/E ratio of -7.87 and a beta of 0.86. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The business’s 50-day simple moving average is $18.67 and its 200-day simple moving average is $19.99.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of KURA. nVerses Capital LLC purchased a new position in shares of Kura Oncology in the 3rd quarter valued at approximately $25,000. SG Americas Securities LLC acquired a new stake in shares of Kura Oncology in the 1st quarter valued at approximately $110,000. Quarry LP acquired a new stake in shares of Kura Oncology in the 2nd quarter valued at approximately $196,000. Entropy Technologies LP acquired a new stake in shares of Kura Oncology in the 1st quarter valued at approximately $218,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Kura Oncology by 64.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company’s stock worth $288,000 after purchasing an additional 5,788 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.